Dia Spectr
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aroda, V. R.
Right arrow Articles by Henry, R. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Aroda, V. R.
Right arrow Articles by Henry, R. R.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Spectrum 16:120-125, 2003
© American Diabetes Association ®, Inc., 2003


Feature Article

Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease

Vanita R. Aroda, MD and Robert R. Henry, MD

Address correspondence and reprint requests to Vanita R. Aroda, MD, University of California, San Diego, VA San Diego Healthcare System, Division of Endocrinology, Diabetes, and Metabolism, 3350 La Jolla Village Drive, #111G, San Diego, CA 92161.

The thiazolidinediones are a unique class of oral antidiabetic agents that has been shown to directly reduce insulin resistance at sites of insulin action, specifically adipose tissue, skeletal muscle, and the liver. By reducing insulin resistance, these drugs influence many of the modifiable cardiovascular risk factors associated with the insulin resistance syndrome, also known as the cardiovascular dysmetabolic syndrome. Such cardiovascular factors are involved in the development of atherosclerosis and include dyslipidemia, hypertension, microalbuminuria, impaired vascular reactivity, and impaired fibrinolysis. Whether these effects of the thiazolidinediones translate to a reduced incidence of cardiovascular events in people with type 2 diabetes remains to be seen.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
P. Velasquez-Mieyer, C. P. Neira, R. Nieto, and P. A. Cowan
Review: Obesity and cardiometabolic syndrome in children
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 61 - 81.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.